Literature DB >> 12486845

Chemical perfusion of the inner ear.

Lance E Jackson1, Herbert Silverstein.   

Abstract

In general, chemical perfusion therapy of inner ear disease is safe, inexpensive, and easy to perform. High inner ear medication concentrations can be achieved while minimizing systemic side effects. Most delivery methods are minimally invasive and can be performed in the office. The treatment is usually well accepted by patients. Vertigo control rates for Meniere's disease have been excellent--rivaling other prominent surgical treatments--allowing intratympanic therapy to become the most prominent first-line treatment for Meniere's disease. Side effects of ototoxicity occurring in approximately 30% of patients remain as one of the primary hurdles to overcome. Most patients who experience hearing loss, however, do not complain of the loss and are simply happy to be free of their vertigo attacks. The use of oral steroids to rescue and preserve hearing during gentamicin perfusion remain promising, and complete recovery and even hearing improvement have been observed [30]. Steroid perfusion of the inner ear also is variably effective for the treatment of SSHL, and is particularly indicated when oral steroids fail or are contraindicated due to other health reasons. Many inner ear perfusion methods and philosophies of treatment exist. Each technique has its associated advantages and disadvantages, and the individual surgeon must decide which technique to use in concordance with the patient's disease and expectations. In the future, new medications likely will be developed to treat certain types of inner ear disease, including SSHL, tinnitus, and various forms of vertigo. These medications can be administered by direct chemical perfusion of the inner ear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486845     DOI: 10.1016/s0030-6665(02)00023-3

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  8 in total

Review 1.  Intratympanic steroid therapy for inner ear diseases, a review of the literature.

Authors:  M J R C Alles; M A der Gaag; R J Stokroos
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

2.  Nitinol actuated soft structures towards transnasal drug delivery: a pilot cadaver study.

Authors:  Manivannan Sivaperuman Kalairaj; Bok Seng Yeow; Chwee Ming Lim; Hongliang Ren
Journal:  Med Biol Eng Comput       Date:  2020-01-11       Impact factor: 2.602

3.  Microperforations significantly enhance diffusion across round window membrane.

Authors:  Catherine M Kelso; Hirobumi Watanabe; Joseph M Wazen; Tizian Bucher; Zhen J Qian; Elizabeth S Olson; Jeffrey W Kysar; Anil K Lalwani
Journal:  Otol Neurotol       Date:  2015-04       Impact factor: 2.311

4.  Use of intratympanic dexamethasone for the therapy of low frequency hearing loss.

Authors:  Necat Alatas
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-20       Impact factor: 2.503

Review 5.  Inner ear drug delivery for auditory applications.

Authors:  Erin E Leary Swan; Mark J Mescher; William F Sewell; Sarah L Tao; Jeffrey T Borenstein
Journal:  Adv Drug Deliv Rev       Date:  2008-09-21       Impact factor: 15.470

Review 6.  Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss.

Authors:  Lilun Li; Tiffany Chao; Jason Brant; Bert O'Malley; Andrew Tsourkas; Daqing Li
Journal:  Adv Drug Deliv Rev       Date:  2016-01-12       Impact factor: 15.470

7.  Permeability of the round window membrane is influenced by the composition of applied drug solutions and by common surgical procedures.

Authors:  Anthony A Mikulec; Jared J Hartsock; Alec N Salt
Journal:  Otol Neurotol       Date:  2008-10       Impact factor: 2.311

8.  Intratympanic methylprednisolone as rescue therapy in sudden sensorineural hearing loss.

Authors:  Igor Teixeira Raymundo; Fayez Bahmad; Jairo Barros Filho; Thaís Gonçalves Pinheiro; Nilda Agostinho Maia; Carlos Augusto Oliveira
Journal:  Braz J Otorhinolaryngol       Date:  2010 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.